The challenges ahead for psychedelic ‘medicine’

This article is a narrative viewpoint rather than a report of new empirical research or a systematic review. The extracted text does not present a formal methods section, search strategy or prespecified inclusion criteria. Instead, the paper synthesises methodological and implementation issues drawing on previous literature, the authors' own prior work and their experience in the field. Where empirical findings are cited—for example the authors' earlier systematic review that identified six randomised controlled trials of classical psychedelics in mood disorders—those findings are presented as supporting evidence within the commentary. The authors do not report performing a new systematic evidence search or quantitative meta-analysis within this extracted text.

The paper organises its findings as a series of challenge-focused themes rather than primary/secondary outcomes. Key points are reported below in the same thematic order used by the authors. Blinding/masking: The investigators emphasise that effective blinding is central to limiting conscious and unconscious bias in clinical trials. Citing their prior systematic review, they note that of six RCTs of classical psychedelics in mood disorders, only three reported on participant masking and in those trials almost 100% of participants could correctly guess when they had received a psychedelic. The authors argue that correct participant belief about allocation can amplify expectancy effects and alter placebo responses, so trials should assess blinding and apply appropriate statistical techniques to those assessments. Therapeutic alliance: Psychedelic interventions are commonly paired with psychotherapy, which complicates standard drug-trial frameworks. A strong therapeutic alliance can predict outcome, and therapists may become (consciously or unconsciously) differentially responsive if they suspect treatment allocation. Bespoke integration therapies given to the psychedelic arm may be inappropriate or aversive for control participants, further confounding comparisons. Expectancy: The authors define response expectancy as patients' beliefs about their own non-volitional response to treatment and note that heightened media attention and trial procedures (for example questionnaires probing mystical-type experiences) may increase expectancy effects. Expectancy need not be a confound if pre-randomisation, but it can become one if post-randomisation variables such as unblinding or differential therapeutic contact open causal pathways between treatment and outcome. Other biases: Standard threats to validity—regression to the mean, sampling bias and attrition—are also relevant in psychedelic research. Self-selection is flagged as a particularly salient problem, contributing to non-representative sampling and underrepresentation of ethnic and demographic minorities. The authors highlight concerns about the close ties between some investigators and advocacy or commercial interests, which could introduce experimenter bias. Statistical power: Most psychedelic trials so far have small sample sizes, constrained by limited funding and the resource intensity of each participant's treatment (often complex, treatment-resistant populations). Larger multicentre collaborations and the arrival of industry-funded RCTs may increase power; the authors emphasise that robust mediation or confounder-adjustment analyses will require substantially larger samples than currently typical. Use of real-world/supplementary evidence: Recognising constraints on conducting ideal RCTs, the paper outlines alternative evidence sources—epidemiological studies, surrogate and digital biomarkers, case reports and n = 1 studies—but cautions that each has methodological weaknesses and that convergent evidence would be needed. The double-blind RCT remains the regulatory gold standard, and it is unclear whether alternative approaches would suffice for drug approval. Transparency: The authors argue that trial transparency is inadequate in psychedelic research: registries often contain only minimal information, statistical analysis plans and adverse event metrics are frequently missing, and completed studies are not always fully reported. They recommend prospective publication of full trial protocols in peer-reviewed journals. Funding: Philanthropic funding has underpinned the recent revival of psychedelic research but, the authors caution, philanthropic review processes may not match the rigour of public research councils. They welcome moves toward public funding—citing an Australian government allocation of $15M for psychedelic RCTs—and note the growing role of commercial companies, stressing that transparent practices will be critical as industry involvement grows. Effects of scheduling: The authors describe scheduling (most psychedelics remaining in Schedule 1) as a substantial barrier to research, increasing time and expense and often prohibiting outpatient or real-world studies. This restriction limits evidence on long-term effects and microdosing, and pushes some research into self-blinding or observational citizen-science methods that face verification challenges. Scheduling also likely contributes to self-selection and referral biases. Ethical concerns regarding psychedelic-assisted psychotherapy: Because psychedelics can induce profound changes in consciousness and perceived loss of control, the authors raise risks of power differentials and potential abuse between therapists and patients. They recommend risk-management techniques in trials such as using multiple practitioners, transparent practices (for example video recording dosing sessions) and supervision by experienced clinicians. Unregulated self-treatment: The commentary warns that mainstreaming psychedelics could increase unregulated self-treatment, with attendant risks—particularly for people with contraindications (for example a history of psychosis) and in the absence of medical screening and integration support. The authors suggest qualitative research into community therapeutic use to characterise these risks. Integration into healthcare systems: Practical integration challenges receive detailed attention. Current psychedelic therapy models are resource intensive—typically requiring on the order of 40 hours of practitioner contact—whereas routine primary care often provides only a few hours of therapy. The authors present an illustrative cost calculation: if 2% of a national population (about 100,000 people) sought treatment at $15,000 each, the total would be $1.5 billion, exceeding some countries' annual medicines budget. A specific therapy example estimates three 8-hour sessions with two therapists (48 hours) at $250 per hour would cost about $12,000, before adding medical oversight, drug and facility costs. They conclude that substantial infrastructure, workforce training and funding would be required, and express scepticism about scaling current resource-heavy models. The authors propose investigating lower-cost or hybrid delivery models, including online resources, but insist such alternatives must be evaluated in clinical trials. Incorporating frameworks from traditional medical models: Finally, the paper notes tensions between traditional, ritualised uses of psychedelics (for example psilocybin and ayahuasca) and reductionist approaches of RCT-based modern medicine. The authors call for ethnographic research and leadership by Indigenous peoples to avoid cultural appropriation and to preserve traditional practices as medicalisation proceeds. Overall summary: The investigators acknowledge that early pioneering trials may not meet all the methodological criteria they outline, but they urge that research practices improve. They stress the need to remain objective and realistic about the significant challenges that must be addressed if psychedelic interventions are to be responsibly integrated into healthcare.

The authors interpret their thematic review as a call for increased methodological rigour, transparency and systemic preparedness as psychedelic research progresses. They argue that problems with blinding, expectancy, differential psychotherapy, participant selection and low sample sizes threaten internal validity and could either produce false positives or mask true effects, depending on how nonspecific factors operate. Positioning their conclusions relative to earlier work, the paper notes that while early trials have generated excitement, this should not replace systematic assessment; where empirical data exist (for example on unblinding rates in small RCTs) those data underscore the need for better trial design and blinding assessment. The authors also situate regulatory and implementation challenges—such as current Schedule 1 classifications, limited transparency and predominantly philanthropic funding—as structural barriers that may bias the evidence base and limit equitable access. Key limitations and uncertainties acknowledged include the resource-intensity of psychedelic therapy models, uncertain scalability, and the methodological limits of alternative evidence sources if double-blind RCTs remain infeasible. The extracted text does not present a formal limitations subsection specific to the viewpoint format, but the authors repeatedly note where evidence is sparse and where proposals require further empirical testing. Implications discussed by the authors cover research practice, regulation and healthcare delivery. Recommendations include routine assessment of blinding and expectancy, prospective publication of trial protocols and analysis plans, setting minimum demographic recruitment targets to improve representativeness, seeking public research-funding mechanisms, and designing ethical safeguards for therapist–patient interactions. For health systems, the authors call for trials of lower-cost delivery models and careful evaluation of scalability and acceptability. Respect for Indigenous knowledge and culturally led research are highlighted as essential when translating traditional practices into regulated medical contexts. The authors conclude that, although psychedelics show early promise, a realistic and measured approach is required to navigate the complex path from promising trials to safe, equitable clinical implementation.